GLP-1 Drug Liraglutide Promotes Rotator Cuff Healing by Reducing Inflammation and Cell Stress in Rat Study | Research

The takeaway

Liraglutide reduced inflammation, prevented tendon cell death, and restored biomechanical strength in a rat rotator cuff injury model by activating the AMPK/SIRT1 pathway.

Biomechanical strength restored
Liraglutide not only reduced molecular markers of inflammation but also functionally restored tendon strength in a rat rotator cuff injury model

What the researchers found

Liraglutide significantly inhibited IL-1β-induced inflammation in tendon cells in vitro, enhanced tendon cell anabolism (tissue building), and upregulated the AMPK/SIRT1 pathway. Mechanistically, the GLP-1 receptor was found to interact with SIRT1 to prevent tendon cell apoptosis (programmed cell death) and endoplasmic reticulum stress.

In the in vivo rat rotator cuff injury model, liraglutide effectively promoted tissue regeneration and restored biomechanical strength of the repaired tendon, demonstrating both molecular and functional therapeutic effects.

Why it matters

Rotator cuff injuries are extremely common — affecting millions annually — and healing is often poor due to chronic inflammation at the repair site. Finding that an already-approved drug like liraglutide can reduce tendon inflammation and improve healing could open a new off-label application, potentially improving outcomes for the many patients who struggle with rotator cuff recovery.

How the study worked

The study used both in vitro and in vivo approaches. In vitro, tendon cells were treated with IL-1β to induce inflammation, then treated with liraglutide to assess effects on inflammation, apoptosis, and endoplasmic reticulum stress. The AMPK/SIRT1 signaling pathway was investigated mechanistically. In vivo, a rat rotator cuff injury model was used to evaluate liraglutide's effects on tissue regeneration and biomechanical strength recovery.

What this study cannot tell us

This is a preclinical study using cell culture and a rat model. Rat rotator cuff anatomy and healing differ from humans. The study did not test different doses or timing of liraglutide treatment. Long-term durability of the healing effect beyond the study period is unknown. Translation to clinical use would require human trials.

How to read the evidence

This is a preclinical study combining in vitro cell culture and an in vivo rat model. While the dual approach provides strong mechanistic evidence with functional outcomes, results have not been validated in humans.

When this study was published

Published in 2026, this is a very recent study reflecting the current expansion of GLP-1 drug research into musculoskeletal applications.

The bigger picture

This study adds musculoskeletal healing to the expanding list of non-metabolic applications for GLP-1 receptor agonists. With growing evidence of anti-inflammatory benefits in the lungs, heart, kidneys, and brain, this research suggests GLP-1 activation may be a broadly protective mechanism that extends to tendons — opening potential applications in orthopedic medicine.

Questions still open

Would liraglutide improve rotator cuff healing outcomes in human patients undergoing surgical repair?
Could local injection of liraglutide at the repair site be more effective than systemic administration for tendon healing?
Does the AMPK/SIRT1 mechanism explain anti-inflammatory effects of GLP-1 drugs observed in other tissues as well?

Common questions

Could liraglutide help heal rotator cuff injuries in people?

This study provides the first evidence that liraglutide can promote rotator cuff healing in rats by reducing inflammation and restoring tendon strength. However, it has not been tested in humans for this purpose. Since liraglutide is already an approved drug, it could potentially be studied for rotator cuff healing more quickly than a completely new drug, but clinical trials would be needed first.

How does liraglutide help tendons heal?

The study found that liraglutide activates a molecular pathway called AMPK/SIRT1 in tendon cells. This pathway reduces inflammation triggered by IL-1β (a key inflammatory molecule), prevents a type of harmful cellular stress called endoplasmic reticulum stress, and blocks programmed cell death. Together, these effects create a more favorable environment for tissue regeneration and tendon repair.

Read the original research

GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.

International immunopharmacology, 169, 116010

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Xiong; Chi, Ruimin; Xu, Jingting; Meng, Chen; Wang, Zhenggang; Ruo, Wanjun; Xin, Fei; Xu, Tao; Guo, Fengjing; Wang, Genchun; Ye, Yaping. (2026). GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.. International immunopharmacology, 169, 116010. https://doi.org/10.1016/j.intimp.2025.116010